Dr Edwin Moses
Edwin is a highly respected executive with over 30 years’ experience in the life sciences sector. Most recently, he spent 12 years as Chief Executive Officer (CEO) of Ablynx, which was acquired by Sanofi for $4.8bn in June 2018, delivering significant shareholder value and overseeing approval of its first product, indicated for a rare blood disease. During his tenure, he led two successful IPOs on EuroNext and NASDAQ respectively, as well as presiding over workforce growth from fifty people to almost five-hundred. Prior to this, he was CEO and Executive Chairman of Oxford Asymmetry International (OAI) where he oversaw a series of venture rounds and an IPO on the London Stock Exchange, valuing the company at £120m. In 2000, Edwin led the £316m merger of OAI with Evotec Biosystems. Between Ablynx and OAI, Edwin has successfully raised over €500m in equity and debt financing. Furthermore, Edwin has more than 25 years of Board level experience with more than 10 other European life sciences companies, where he has advised on broad and multiple growth strategies including venture capital fundraisings, IPOs and acquisitions. Today he is also Chairman of Achilles Therapeutics and Virion Biotherapeutics. Edwin obtained his PhD in Chemistry from Sheffield University.
Dr Antonin de Fougerolles
Chief Executive Officer and Director
Tony has over 20 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and successfully advancing 3 new drug modalities towards the market (RNAi, modified mRNA, single domain antibodies) and in helping build several multi-billion dollar companies from start-up stage. Prior to joining Evox, Tony was CSO of Ablynx, where he led the company’s non-clinical R&D operations, including Discovery, Pharmacology, CMC, and Clinical Trial Drug Supply, and played a key role in the approval of the 1st single domain antibody drug. Prior to Ablynx, Tony was founding CSO at Moderna Therapeutics pioneering modified mRNA as a new therapeutic modality, CSO of antibody-based immune-oncology company Tolerx Inc, and VP Research at Alnylam where he helped develop RNAi as a new therapeutic modality, including overseeing development of the now 1st approved RNAi delivery system. In addition, Tony has been Principal Investigator on over $80m in grants, has over 60 scientific publications, and is an inventor on over 90 issued U.S. patents. He also serves on the Scientific Advisory Boards of MiNA Therapeutics and LIfT BioSciences. Tony earned his Ph.D. in Immunology from Harvard University.
Dr Andrew McLean
Andy is the lead life sciences investor at Oxford Sciences Innovation plc overseeing a portfolio of 10 life sciences companies. In this role he was also involved in seeding Evox Therapeutics, Vaccitech, and Lab282. Prior to joining OSI he was a consultant in McKinsey & Company’s London office. He trained as a Doctor at the University of Western Australian before taking a degree in philosophy, politics & economics at Christ Church, University of Oxford.
Amrit is a Managing Director, Private Investments at Redmile Group, LLC, a health care-focused investment firm based in San Francisco and New York. Prior to Redmile, Amrit spent 10 years at Weintraub Capital Management, an investment firm based in San Francisco, as both an analyst and portfolio manager. Prior to Weintraub, he was an associate and an analyst at Robertson Stephens, a San Francisco-based investment bank. Amrit received a BA in Economics from Columbia University and an MBA from The Anderson School at UCLA.
Sarah Gordon Wild
Sarah was Managing Director, Management Committee Member and Senior Healthcare analyst at Lone Pine Capital LLC from 1998 to 2003 and has served on the Boards of Immunomedics and Praecis Pharmaceuticals. Previously, she was a Senior Biotechnology/Health Care Analyst for over 15 years at Amerindo Investments Advisors, Hambrecht & Quist, Kleinwort Grieveson, and Greig Middleton. She currently serves as Non-Executive Director of Oxford Nanopore Technologies, Board Member of Lone Pine Capital LLC’s Offshore Funds and is a Partner and Board Member of Duke's Auctioneers in Dorset. She is a graduate from both Aberdeen University and Imperial College, University of London.
Dr Adam Stoten
Adam is Chief Operating Officer for Oxford University Innovation Ltd (OUI), the technology transfer company of the University of Oxford, responsible for translating the intellectual property, ideas and expertise arising from Oxford’s research into new products and services. He has more than 15 years’ experience in commercial roles encompassing business development and licensing, new venture formation, product development, lobbying/advocacy and general management. Prior to his current role, Adam led the Life Sciences Licensing & Ventures Group at OUI, where he oversaw the formation of more than 20 new spin out companies and led the creation of LAB282, a £13m drug discovery partnership with Oxford Sciences Innovation plc and Evotec AG. Between 2010 and 2013 Adam worked as Deputy General Manager for the Oxford-Emergent Tuberculosis Consortium Ltd, a joint venture between the University of Oxford and Emergent BioSolutions Inc, which raised more than $30m to conduct the first ever efficacy study of a next generation TB vaccine in infants. Prior to this Adam worked in healthcare consulting with Technomark Ltd and then in increasingly senior commercialisation roles at OUI. Adam obtained his PhD in Immunology from Nottingham University.
Dr Per Lundin
Chief Operating Officer and Founder Director
Per has over 10 years of experience in advising, founding and leading biotech companies developing groundbreaking therapies. Per developed and structured the IP and technology portfolio that formed the basis for the founding and £10m Series A financing of Evox and has acted as the company’s Chief Operating Officer since inception. Prior to founding Evox, Per co-founded and served as Chief Executive and Board member of IsletOne Therapeutics, a clinical stage cell therapy company developing a proprietary mesenchymal stromal cell therapy for the treatment of acute respiratory distress syndrome and autoimmunity. Previously, Per managed a European business development channel for Thomson Reuters IP & Science and prior to that qualified as a European Patent Attorney in the biotech practice of one of the largest European IP law firms, advising clients on matters ranging from innovation strategy to commercialisation. He started his career as a Research Scientist with Apollo Life Sciences working on nanoparticle drug delivery. Per earned his PhD at the Karolinska Institute, holds an MSc in Biotechnology Engineering, and an MBA from Stockholm University School of Business.
Professor Matthew Wood
Matthew is Professor of Neuroscience and Deputy Head of the Medical Sciences Division at the University of Oxford and directs the Laboratory of RNA Biology and Neuromuscular Disease. Matthew is also a pioneering international leader in the field of exosome biology, publishing in Nature Biotechnology in 2011 the landmark discovery that exosomes could be developed into a therapeutic drug modality. Matthew has continued his pioneering work in the exosome field and is one of the co-founders of Evox Therapeutics. Matthew is also a world expert in the field of oligonucleotide therapies and co-leads a major international translational medicine collaboration (MDEX Consortium) that helped develop Eteplirsen, the first ever treatment for Duchenne muscular dystrophy. Matthew is a Director of the University of Oxford’s technology transfer organisation (Oxford University Innovation) and is also a Founder and Director of PepGen Ltd., an Oxford-based start-up biotech company. He also serves on the Scientific Advisory Board of Sarepta Therapeutics. Matthew graduated in Medicine from the University of Cape Town, working in clinical neuroscience before gaining a doctorate in Physiological Sciences from the University of Oxford.